Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of NIH funding cuts that support vital biomedical research across the U.S.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces presentations featuring the Company ...

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to prostate cancer poster session. Dr. Zachary Klaassen presented the results of a population-based analysis evaluating ...